Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Diagnostic or test agent produces in vivo fluorescence
Reexamination Certificate
2008-05-20
2008-05-20
Powers, Fiona T (Department: 1626)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Diagnostic or test agent produces in vivo fluorescence
Reexamination Certificate
active
11498944
ABSTRACT:
The present invention is directed to a non-isotopic methods for the in vitro and in vivo detection of hydroxyapatite-positive cells and structures.
REFERENCES:
patent: 5453505 (1995-09-01), Lee et al.
patent: 6027709 (2000-02-01), Little et al.
patent: WO 96/17628 (1996-06-01), None
patent: WO 98/22146 (1998-03-01), None
patent: WO 98/22146 (1998-03-01), None
patent: WO 98/48838 (1998-11-01), None
patent: WO 98/48846 (1998-11-01), None
patent: WO 00/16810 (2000-03-01), None
Zaheer et al., Nature Biotechnology, 19(12), 1148-1154, Dec. 2001.
Altkorn, D., and Vokes, T., “Treatment of Postmenopausal Osteoporosis,”JAMA, 285(11):1415-1418, (2001).
Caesar, J., et al., “The Use of Indocyanin Green in the Measurement of Hepatic Blood Flow and as a Test of Hepatic Function,”Clin. Sci., 21:43-57, (1961).
Chance, B., “Near-Infrared Images Using Continuous, Phase-Modulated, and Pulsed Light with Quantitation of Blood and Blood Oxygenation,”Annals of The New York Academy of Sciences, 838:29-45, (1998).
Devoisselle, J.M., et al., “Measurement of In Vivo Tumorous/Normal Tissue pH Localized Spectroscopy Using a Fluorescent Marker,”Optical Engineering, 32(2):239-243, (1993).
Eastell, R., “Treatment of Postmenopausal Osteoporosis,”The New England Journal of Medicine, 338(11):736-746, (1998).
Farkas, D.L., et al., “Non-Invasive Image Acquisition and Advanced Processing in Optical Bioimaging,”Computerized Medical Imaging and Graphics, 22:89-102, (1998).
Fujisaki, J., et al., “Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. I: Synthesis and In Vivo Characterization of Osteotropic Carboxyfluorescein,”Journal of Drug Targeting, 3:273-282, (1995).
Fujisaki, J., et al., “Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. III: Pharmacokinetics and Targeting Characteristics of Osteotropic Carboxyfluorescein,”Journal of Drug Targeting, 4:117-123, (1996).
Fujisaki, J., et al., “Physicochemical Characterization of Bisphosphonic Carboxyfluorescein for Osteotropic Drug Delivery,”J. Pharm. Pharmacol., 48:798-800, (1996).
Fujisaki, J., et al., “Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. IV Effects of Osteotropic Estradiol on Bone Mineral Density and Uterine Weight in Ovariectomized Rats,”Journal of Drug Targeting, 5(2):129-138, (1997).
Fujisaki, J., et al., “Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. V. Biological Disposition and Targeting Characteristics of Osteotropic Estradiol,”Biol. Pharm. Bull., 20(11):1183-1187, (1997).
Glorieux, F.H., et al., “Cyclic Administration of Pamidronate in Children With Severe Osteogenesis Imperfecta,”The New England Journal of Medicine, 339(14):947-952, (1998).
He, Y.L., et al., “Measurement of Blood Volume Using Indocyanine Green Measured with Pulse-Spectrophotometry: Its Reproducibility and Reliability,”Crit. Care Med., 26(8):1446-1451, (1998).
Hirabayashi, H., et al., “Bone-Specific Delivery and Sustained Release of Diclofenac, A Non-Steroidal Anti-Inflammatory Drug, Via Bisphosphonic Prodrug Based on the Osteotropic Drug Delivery System (ODDS),”Journal of Controlled Release, 70:183-191, (2001).
Karrar, S., et al., “Photochemotherapie Kutaner Rektumkarzinom-Metastasen mit Idocyaningrün,”Deutsche Medizinische Wochenschrift, 122:1111-1114, (1997).
Klenner, T., et al., “Anticancer-Agent-Linked Phosphonates with Antiosteolytic and Antineoplastic Properties: A Promising Perspective in the Treatment of Bone-Related Malignancies?,”J. Cancer Res. Clin. Oncol., 116:341-350, (1990).
Lin, J.H., et al., “Physiological Disposition of Alendronate, A Potent Anti-Osteolytic Bisphosphonate, In Laboratory Animals,”Drug Metabolism and Disposition, 19(5):926-932, (1991).
Mahmood, U., et al., “Near-Infrared Optical Imaging of Protease Activity for Tumor Detection,”Radiology, 213:866-870, (1999).
Martin, M.B., et al., “Biophosphonates Inhibit the Growth ofTrypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplamsa gondii, andPlasmodium faciparum: A Potential Route to Chemotherapy,”J. Med. Chem., 44:909-916, (2001).
Mujumdar, R.B., et al., “Cyanine Dye Labeling Reagents: Sulfoindocyanine Succinimidyl Esters,”Bioconjugate Chemistry, 4(2):105-111, (1993).
Mundy, G.R. and Yoneda, T., “Bisphosphonates as Anticancer Drugs,”The New England Journal of Medicine, 339(6):398-400, (1998).
Ntziachristos, V., et al., “Concurrent MRI and Diffuse Optical Tomography of Breast After Indocyanine Green Enhancement,”PNAS, 97(6):2767-2772, (2000).
Quaresima, V., et al., “Identification and Quantification of Intrinsic Optical Contrast for Near-Infrared Mammography,”Photochemistry and Photobiology, 67(1):4-14, (1998).
Rockson, S.G., et al., “Photoangioplasty for Human Peripheral Atherosclerosis Results of a Phase I Trail of Photodynamic Therapy With Motexafin Lutetium (Antrin),”Circulation, 102:2322-2324, (2000).
Rogers, M.J., et al., “Cellular and Molecular Mechanisms of Action of Bisphosphonates,”Cancer(Supplement), 88 (12):2961-2978, (2000).
Zaheer, A., et al., “Near-Infrared Fluorescence Imaging of Osteoblastic Activity,”Proc. Am. Assoc. Cancer Res. Ann. 42:483 (2001); 92ndAnnual Meeting of the American Association for Cancer Research; New Orleans, LA, USA (Mar. 24-28, 2001): Abstract No. 2602.
Flesch, et al., “Determination of the Bisphosphonate Pamidronate Disodium in Urine by Pre-Column Derivatization with Fluorescamine, High-Performance Liquid Chromatography and Fluorescence Detection,”Journal of Chromatography, 489(2):446-451 (1989).
Beth Israel Deaconees Medical Center
Powers Fiona T
LandOfFree
Non-isotopic detection of osteoblastic activity in vivo... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-isotopic detection of osteoblastic activity in vivo..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-isotopic detection of osteoblastic activity in vivo... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3937848